Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Lymphoma 27Leukemia 16Lung Neoplasms 13Neuroblastoma 12Burkitt Lymphoma 11Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Sarcoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Central Nervous System Neoplasms 9Brain Neoplasms 9Teratoma 8Carcinoma, Non-Small-Cell Lung 7Wilms Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Leukemia, Myeloid, Acute 6Testicular Neoplasms 5Lymphoma, Non-Hodgkin 5Ovarian Neoplasms 4Medulloblastoma 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Endodermal Sinus Tumor 4Dendritic Cell Sarcoma, Interdigitating 4Carcinoma, Embryonal 4Sarcoma, Ewing 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × Etoposide × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡